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Abstract
Background: Use of donor blood in congenital cardiac surgery increases the risk for post-operative morbidity and
mortality. To reduce the need for allogenic blood transfusion a technique for peri-operative mechanical red cell
salvage is applied. Blood from the operation site is collected in a reservoir, processed, passed through a lipophilic
filter and returned to the patient. Influence of this cellsaver system on coagulation, fibrinolysis and inflammatory
markers is known. To our knowledge no studies have been performed on the effects of autotransfusion on drug
concentrations. A clinically relevant drug dose could potentially be returned to the patient through the auto-
transfused blood, leading to unwanted drug reactions post-operatively. We aimed to measure drug concentrations
in blood salvaged from the operation site and in the auto-transfused blood to determine if a clinically relevant drug
dose is returned to the patient.
Methods: The study was performed at the Department of Cardiothoracic Surgery of a tertiary university hospital.
Blood samples were taken from the reservoir, after processing before the lipophilic filter, the auto-transfused blood,
and the waste fluid. Samples were stored at − 80 C and drug concentration for sufentanil, propofol, midazolam and
cefazolin were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Drug
concentrations measured in the reservoir and the auto-transfused blood were compared and the relative reduction
was calculated for each patient.
Results: Blood samples were taken from 18 cellsaver runs in 18 patients, age 0–13 years. Drug concentrations in
the reservoir were comparable to concomitant concentrations in the patient. For sufentanil 34% (median, IQR 27–
50) of drug concentration was retained from the reservoir in the auto-transfused blood, for midazolam 6% (median,
IQR 4–10), for cefazolin 5% (median, IQR 2–6) and for propofol 0% (median, IQR 0–0) respectively.
Conclusion: Depending on the drug, up to 34% of the drug concentration salvaged from the operation site is
returned to the patient through autotransfusion, potentially causing unwanted drug reactions post-operatively.
Additionally, influence of a cellsaver system should be considered in pharmacological research during and after
congenital cardiac surgery and could result in dose adjustments in the postoperative phase.
Trial registration: Registration at the Dutch Trial Registry (NTR3579) at August 14 2012.
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Background
Allogenic donor blood is used in almost all small patients
undergoing congenital cardiac surgery. This is mainly due
to hemodilution caused by the use of cardiopulmonary by-
pass (CPB). The technique of mechanical red cell salvage
is applied during congenital cardiac surgery. Equipment
designed to undertake this task is routinely referred to as
an autotransfusion or cellsaver system. Using the cellsaver
system blood from the operation site is collected in a res-
ervoir, processed, passed through a lipophilic filter after
which it is returned to the patient. The use of donor blood
during surgery increases post-operative morbidity, mainly
infections [1]. The cellsaver system is used to reduce the
need for allogenic blood transfusion and may therefore
improve the outcome after surgery. The auto-transfused
blood is usually returned to the patient postoperatively on
the paediatric intensive care unit (PICU).
Influence of this cellsaver system on coagulation, fi-
brinolysis and inflammatory markers is known [2, 3]. In
contrast, published literature on the effects of blood loss,
volume replacement and use of a cellsaver system on
plasma drug concentration is limited. Sue et al. investi-
gated the effect of surgical blood loss and fluid replace-
ment on antibiotic pharmacokinetics in adult patients
during cardiac surgery and determined the total cefazo-
lin plasma concentration at several time points [4]. In
their study a cellsaver system was used in six of eight pa-
tients. Reinfusion of cefazolin-containing blood did not
appear to substantially effect post-operative plasma cefa-
zolin concentration in this study. However, cellsaver use
was not specified per patient and fluid management dur-
ing surgery will have changed since 1989. The authors
state that major pharmacological effects may occur
through infusion of auto-transfused blood in drugs that
are highly protein bound or hydrophilic. Rohling et al.
showed that plasma concentration of muscle relaxants
were stable in autologous blood that was predonated
after induction of anaesthesia and returned by the end of
surgery without processing with a cellsaver system.
Recurarization occurred in two out of 18 studied pa-
tients [5].
To our knowledge, drug concentration in auto-transfused
blood and influence of a cellsaver system on plasma drug
concentrations has not been investigated in infants and
children. However, based on published literature, highly
protein bound or hydrophilic drugs could persist in the
auto-transfused blood. In our clinic, propofol, midazolam,
sufentanil and cefazolin are routinely used anaesthetic
agents that fit this risk profile. Our hypothesis was that po-
tentially relevant drug doses of propofol, midazolam, sufen-
tanil and cefazolin could be returned to the patient through
the auto-transfused blood. This influence could be import-
ant, because it may lead to unwanted drug reactions
post-operatively.
We aimed to measure drug concentrations in blood
salvaged from the operation site and in the blood proc-
essed by a cellsaver system during congenital cardiac
surgery to determine if a clinically relevant drug dose is
returned to the patient.
Methods
The study was performed at the Department of Cardio-
thoracic Surgery of a tertiary university hospital. Induction
and maintenance of anaesthesia was performed by the at-
tending anaesthesiologist as per local protocol. Either in-
halation induction was performed with sevoflurane, or
intravenous induction with midazolam or propofol, sufen-
tanil and pancuronium. Maintenance of anaesthesia was
performed with continuous infusions of sufentanil, mid-
azolam or propofol. Cefazolin was administered before,
during and after the surgical procedure. CPB technique
was dependent on patient weight and operation proced-
ure, and will be described extensively in the CPB-PHARM
study publications. No patient underwent deep
hypothermia or circulatory arrest during the procedure.
We used an Electa cellsaver system (Livanova, München,
Germany), with a 55 ml processing bowl. Cellsaver pro-
cessing was done as per local protocol, according to man-
ufacturer’s settings. Blood from the operation site was
mixed in the suction tubes with heparinized normal saline
to prevent clotting in the tubes. Washing of the cellsaver
blood was done with NaCl 0.9%. After processing, the cell-
saver blood was filtered with a Pall Lipiguard blood filter
(Haemonetics S.A., Signy, Switzerland), resulting in the
end product, the auto-transfused blood. All residual blood
volume from the CPB system was also directly transferred
to and processed by the cellsaver system after decannula-
tion. The auto-transfused blood is composed according to
the standard of the manufacturer, with 55–60% erythro-
cytes in NaCl 0.9%.
Blood samples were taken from the reservoir, after
processing of salvaged blood before the lipophilic filter,
the auto-transfused blood, and from the waste fluid.
Samples were collected at the end of surgery. If there
was a need to run the cellsaver system both during and
after surgery, samples were taken after the first run for
best comparison. Samples were stored at 4o Celsius until
processing. Samples were centrifuged (10 min at
3600 rpm) and the plasma transferred to polypropylene
cryogenic vials with polypropylene screw caps (Sarstedt
Aktiengesellschaft & Co, Nümbrecht, Germany). Sam-
ples were stored at -80o Celsius until analysis.
Drug concentration were measured at the pharmaco-
logical laboratories of the Erasmus MC. A certified re-
search technician from the ISO certified pharmacy
laboratory performed the FDA validated drug analyses.
In all analyses quality control samples are included, as is
obliged in FDA analyses and ISO and GCP certified
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laboratory. Drug concentrations for propofol (Fresenius
Kabi Nederland BV, Zeist, the Netherlands), midazolam
and midazolam metabolites (Actavis Group PTC ehf.,
Hafnarfjördur, Iceland) were measured using LC-MS/MS
(Waters Corp., Milford, MA, USA). Drug concentration
for sufentanil (Hameln Pharma Plus GmbH, Hameln,
Germany) and cefazolin (Kefzol®, Eurocept BV, Ankev-
een, the Netherlands) were measured using LC-MS/MS
(Thermo Fisher Scientific, Waltham, MA, USA).
Lower and upper limits of quantification (LLOQ and
ULOQ, respectively) were: sufentanil, LLOQ 0.25 mcg/
L, ULOQ 50 mcg/L; propofol LLOQ 100 mcg /L, ULOQ
25000 mcg /L; midazolam LLOQ 2 mcg/L, ULOQ 2400
mcg/L; OH-midazolam LLOQ 3 mcg/L, ULOQ 2300
mcg/L, midazolam glucuronide LLOQ 10 mcg/L, ULOQ
3000 mcg/L; cefazolin LLOQ 1 mg/L, ULOQ 100 mg/L.
Drug concentrations for propofol were not measurable
after auto-transfusion and were treated as zero in the
analysis.
Samples size calculation
The sample size was set at 18 patients. Due to a lack of
published literature on this subject, a formal sample size
calculation or power analysis was not considered feas-
ible. The chosen sample size of 18 patients should be
sufficient to estimate the median and the variability of
the drug concentrations with reasonable precision.
Statistical analysis
The ratio between drug concentrations measured in the
reservoir and drug concentrations measured in the
auto-transfused blood was calculated for each patient.
The distributions of the drug concentrations in the res-
ervoir and in the auto-transfused blood and their ratios
were summarized with the median and the interquartile
range (IQR) per drug, to give an indication of the per-
centage of the drug concentration remains in the
auto-transfused blood. The correlation between the ab-
solute drug concentrations measured in the reservoir
and concentrations in the auto-transfused blood were
calculated using Spearman’s rank correlation coefficients.
Drug concentrations did not follow a normal distribu-
tion and were log(10) transformed in order to calculate
the relative reduction. Relative reduction per drug was
calculated by subtracting the log(10) transformed con-
centration in the auto-transfused blood from the log(10)
transformed concentration in the reservoir. The relative
reduction per drug is plotted against the reservoir con-
centration to predict the relative reduction per starting
concentration in Fig. 3a-d, together with a linear regres-
sion line. The R2 was used to show the predictive value
of the drug concentration in the auto-transfused blood
based on the starting concentration in the reservoir, with
a R2 of 0 representing no correlation and a R2 of 1
representing a perfect correlation. The reported R2 and
the 95% confidence interval (CI) in Fig. 3a-d are based
on the linear regression of the log(10) transformed rela-
tive reductions on the log(10) transformed concentra-
tions in the reservoir.
This study was a part of the CPB-PHARM study, in-
vestigating pharmacokinetics (PK) and pharmacodynam-
ics (PD) of routinely used drugs in neonates and
children during cardiac surgery with the use of cardio-
pulmonary bypass (approved by IRB Erasmus MC,
protocol number 2011–400, Dutch Trial Registry
NTR3579). Informed consent was obtained for all study
participants according to Dutch law.
Results
Blood samples were taken from 18 cellsaver runs in 18
paediatric patients. CPB was used in all surgical proce-
dures. Patient characteristics are shown in Table 1. As
shown in Table 1, the cellsaver volume processed post-
operatively is larger than the total blood loss during sur-
gery because of addition of the residual volume of the
CPB. The amount of washing fluid used is mainly
dependent on the processed cellsaver volume. Not all
patients received all tested drugs (see Table 2).
Patient drug concentrations for sufentanil, cefazolin,
midazolam and propofol were measured for the
CPB-PHARM study (MEC2011–400). This study investi-
gates the influence of the cardiopulmonary bypass on
the PK and PD of routinely used drugs during and after
congenital cardiac surgery. Patient drug samples taken
from the arterial catheter during surgery were compared
to drug concentrations measured in the reservoir. Drug
concentrations measured in the reservoir of the cellsaver
system before processing were comparable to concomi-
tant concentrations in the patient, as was expected, and
are thus clinically relevant doses. Drug levels for the dif-
ferent drugs and compartments are shown in Table 2.
For all drugs, the decrease in drug concentration was
largest after washing of the cellsaver blood. The effect of
the lipophilic filter further decreased drug concentra-
tions in all drugs except sufentanil. Considerable con-
centrations of all drugs were measured in the waste
fluid.
Median sufentanil concentration in the reservoir was
0.27 mcg/L (IQR 0.18–0.35). Median sufentanil concen-
tration in the auto-transfused blood was 0.10 mcg/L
(IQR 0.09–0.10). Therefore 34% (median, IQR 27–50) of
drug concentration was retained from the reservoir in
the auto-transfused blood. Detailed concentrations per
sample site and percentage recovery are shown in Table
2 and Fig. 1.
Median midazolam concentrations in the reservoir and
the auto-transfused blood were 192.69 mcg/L (IQR 49.06–
316.42) and 11.87 mcg/L (IQR 7.16–20.16) (6%, median
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IQR 4–10) respectively. Details of midazolam recovery are
shown in Table 2. Biologically active midazolam metabo-
lites, 1-hydroxy-midazolam and midazolam glucuronide,
were also measured. Recovery of 1-hydroxy-midazolam and
midazolam glucuronide was 11% (median, IQR 7–29) and
6% (median, IQR 4–8) respectively. Details of
1-hydroxymidazolam and midazolam glucuronide recovery
are shown in Table 2 and Fig. 1.
Median cefazolin concentration in the reservoir and the
auto-transfused blood was 228.44 mg/L (IQR 118.47–
295.85) and 8.7 mg/L (IQR 5.13–11.44) (5%, median, IQR
2–6) respectively. Detailed concentrations per sample site
and percentage recovery are shown in Table 2 and Fig. 1.
Median propofol concentration in the reservoir and in
the waste fluid was 0.65 mg/L (IQR 0.21–1.86) and
0.18 mg/L (IQR 0.11–0.25) respectively. Propofol
concentration could not be measured after processing
and in the auto-transfused blood. Detailed concentra-
tions per sample site and percentage recovery are shown
in Table 2 and Fig. 1.
The correlations between drug concentrations mea-
sured in the reservoir and concentrations in the
auto-transfused blood are shown in Fig. 2a-e. The rela-
tive reduction per drug is plotted against the reservoir
concentration to predict the relative reduction per start-
ing concentration in Fig. 3a-e.
Discussion
To our knowledge this is the first study to measure drug
concentrations in auto-transfused blood after paediatric
cardiac surgery. Drug recovery varies between drugs in
the auto-transfused blood and not all drugs are found in
Table 1 Patient characteristics
Patient Characteristic N (mean, minimum – maximum)
Age 2 y 6 months (2 months − 13 y 11 months)
Female /male 10 / 8
Surgical procedure





Total peroperative blood loss (ml/kg) 12.6 (1.6–62.7)
Cellsaver volume processed (ml) 290 (135–910)
Cellsaver product after processing (ml/kg) 12 (3.9–26)
Washing fluid used (ml) 783 (300–1200)
Kg: kilogram, ml: millilitre, y: years. Surgical abbreviations: ASD: Atrial Septal Defect, TOF: Tetralogy of Fallot, TCPC: Total Cavopulmonary Connection, CAVSD:
Complete Atrioventricular Septal Defect. Miscellaneous: correction Partial Abnormal Pulmonary Venous Return (1), Chauvaud procedure (1), Mitral Valve
Replacement (1), Correction Subaortic Stenosis (1)
Table 2 Drug concentration per sample site
Drug Patients
(n)










Sufentanil (mcg/L) 18 0.27 (0.18–0.35) 0.10 (0.09–0.12) 0.10 (0.09–0.10) 0.13 (0.10–0.16) 34 (27–50)
Midazolam (mcg/L) 18 192.69 (49.06–
316.42)
18.68 (4.91–29.88) 11.87(7.16–20.16) 56.48 (17.25–75.18) 6 (4–10)
1-hydroxy-midazolam (mcg/
L)





36.41 (15.83–57.13) 29.22 (21.40–41.82) 114.07 (75.33–
189.71)
6 (4–8)
Cefazolin (mg/L) 18 228.44 (118.47–
295.85)
10.50 (6.63–17.47) 8.70 (5.13–11.44) 59.34 (40.68–77.80) 5 (2–6)
Propofol (mg/L) 6 0.65 (0.21–1.86) 0 (0–0)* 0 (0–0)* 0.18 (0.25–0.11) 0 (0–0)
IQR Interquartile range, L Litre, Mcg Microgram, mg Milligram, n.a. Not applicable *Drug concentrations for propofol were not measurable after autotransfusion
and were treated as zero in the analysis
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clinically relevant concentrations. For sufentanil 34%
(IQR 27–50) of drug concentration was retained from
the reservoir in the auto-transfused blood, for midazo-
lam 6% (IQR 4–10), for cefazolin 5% (IQR 2–6) and for
propofol 0% (IQR 0–0), respectively. For midazolam
mainly the 1-hydroxy-midazolam metabolite was recov-
ered in the auto-transfused blood. 1-hydroxy-midazolam
is at least as active as midazolam and may contribute to
the overall activity of midazolam [6]. The potential influ-
ence of the return of auto-transfused blood processed in
a cellsaver system on plasma drug concentration in in-
fants and children has not previously been investigated.
Based on the literature by Sue et al. [4] and our own
experience with extra corporeal membrane oxygenation
(ECMO) circuit characteristics [7], the expectation was
that lipophilic drugs would be sequestered in the syn-
thetic components of the cellsaver system and the lipo-
philic filter and thus be prevented from returning in the
auto-transfused blood whereas more hydrophilic drugs
could be retained in the auto-transfused blood.
Any lipophilic compounds that are left in the
auto-transfused blood after washing should be removed
by the lipophilic filter. According to the manufacturer
proteins and lipids should be completely washed from
the end product so that it contains only erythrocytes
and NaCl 0.9%. We have shown that washing of the cell-
saver blood is the most effective step in clearing drugs
from the auto-transfused blood. However both protein
bound as well as lipophilic drugs were recovered in the
end product. Interestingly sufentanil concentrations
were markedly higher compared to the other lipophilic
drugs. Drug characteristics of sufentanil, propofol and
midazolam regarding protein binding and lipophilicity
are fairly similar. With a logP of 3.95, sufentanil is highly
lipophilic, with 93% protein binding, mainly to albumin.
Propofol and midazolam are also both highly lipophilic
with logP’s of 3.79 and 3.89 respectively, with a slightly
higher protein binding than sufentanil, of 95–99 and
97% respectively. Therefore lipophilicity or protein bind-
ing do not seem to predict drug concentrations in the
auto-transfused blood.
Redistribution of lipophilic drugs from erythrocytes
into the auto-transfused blood could explain why lipo-
philic drugs are recovered. Redistribution may occur be-
cause of a shift of drugs from the erythrocyte to the
NaCl 0.9% solution, or because of haemolysis of the
erythrocyte. Also, measuring propofol by the precipita-
tion method instead of LC-MS/MS may have resulted in
measurable propofol concentrations after processing.
Overall, the recovered absolute drug concentrations of
the tested drugs where low. Therefore the absolute dif-
ferences in plasma drug concentration in the patient and
drug concentration in the auto-transfused blood may
not be substantial.
The hydrophilic drug, cefazolin, was almost entirety
washed from the auto-transfused blood. With a logP of
− 0.58 cefazolin was the most water-soluble drug we
have measured. Our results are probably explained by
the washing of the cellsaver blood with NaCl 0.9%. It is
likely that cefazolin dissolved in the NaCl 0.9% solution
and was washed from the auto-transfused blood, even
though cefazolin concentrations in the waste fluid were
low.
Unwanted drug reactions due to auto-transfused blood
may not be clinically relevant in all patients.
Most at risk for clinical effects are small patients who
have had major cardiac surgery with the use of CPB,
where the volume of returned cellsaver blood is rela-
tively large compared to the patient’s own circulating
volume. Also, due to long CPB time, organ perfusion
Fig. 1 drug recovery per sample site (%). Drug concentration in the reservoir is set as 100%
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Fig. 2 a-e correlation of drug concentration in the reservoir and the auto-transfused blood
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will be decreased, resulting in a lower clearance of drugs
from the body [8]. Returning a large volume of
auto-transfused blood to a small patient with a
decreased drug clearance could lead to an accumulation
of drugs, resulting in adverse effects and toxicity espe-
cially for sufentanil. Also, the cellsaver blood is generally
Fig. 3 a-e relative reduction predicted by concentration in reservoir (with dotted line 95% CI)
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administered as a bolus, rather than a continuous infu-
sion. This may be particularly problematic in patients
who are not on mechanical ventilation when the
auto-transfused blood is administered.
However, the concentration of sufentanil in the
auto-transfused blood is 0.1 mcg/L. In a worst case sce-
nario, when 1 l of auto-transfused blood is returned to a
patient with a bodyweight of 3 kg, the sufentanil dose
administered with the auto-transfused blood would be
0.033 mcg/kg. The target sufentanil dose at induction of
anaesthesia is 0.6 mcg/kg [9]. Therefore, if the
auto-transfused blood is returned to the patient during
or very shortly after surgery, the sufentanil concentra-
tion in the patient is higher than the sufentanil concen-
tration in the auto-transfused blood and dilution of
plasma sufentanil concentration will occur. If the
auto-transfused blood is given in a bolus sometime after
sufentanil is stopped, a peak in plasma concentration
may still occur.
Influence of the auto-transfused blood on adverse drug
reaction is therefore dependent on weight of the child,
plasma drug concentration at the time of cellsaver pro-
cessing, and amount, speed and timing of administration
of the auto-transfused blood.
The influence of cellsaver systems should be
accounted for when performing pharmacological trials
after cardiac surgery. Optimizing drug dosing in neo-
nates, infants and children during and after cardiac sur-
gery is important to improve clinical care, especially in
an era where fast track recovery is becoming more im-
portant. Ideally, potential effects of the CPB- and cellsa-
ver systems on drug concentrations should be
incorporated in dosing advices [8]. The current study
provides insight into the potential return of drugs
through auto-transfused blood. Population pharmaco-
kinetics can be used to determine subsequent dose ad-
justments of the investigated drugs [8, 10].
Future research should focus mainly on lipophilic an-
aesthetic drugs that could cause a potential adverse reac-
tion when given to patients postoperatively through the
auto-transfused blood. Also, future endeavours should
aim to incorporate the results of the CPB-PHARM trial
and the results of this trial into a new dosing regimen
for routinely used drugs for neonates, infants and chil-
dren during and after cardiac surgery. This new dosing
regimen will take into account the influence of the CPB
and the cellsaver system.
Conclusion
Depending on the drug, up to 34% of the drug concen-
tration salvaged from the operation site is returned to
the patient through autotransfusion, potentially causing
unwanted drug reactions post-operatively. Additionally,
influence of a cellsaver system should be considered in
pharmacological research during and after congenital
cardiac surgery.
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